Many health plans, including State Medicaid programs require less expensive generics to higher-priced brand name drugs. Some require step therapy where patients have to start on the least expensive drug in a therapuetic category and are only alllowed to receive more expensive drugs if they fail on the initial therapy. While this may seem prudent, this study at least should cause us to pause and further evaluate the data.